A Systematic Review on the Incidence of Major Coronavirus-associated Cardiovascular Diseases and Therapeutic Approaches during the COVID-19 Pandemic
Romina Rezvani
1
(
Medical Student, Islamic Azad University of Medical Science, Tehran, Iran
)
Mohammad Karimi
2
(
Department of Infectious Disease, Infectious Disease Specialist, Imam Reza Hospital, Amol, Mazandarān, Iran
)
Yahya Ebrahimi
3
(
Assistant Professor of Cardiology, Department of Cardiology, School of Medicine, Shahid Madani Hospital, Lorestan University of Medical Sciences, Khorramabad, Iran
)
Keywords: Heart, Cardiovascular Diseases, COVID-19, SARS-CoV-2, Cardiac Complications, Myocardial Damage, Patient,
Abstract :
During the COVID-19 pandemic, people with cardiovascular disease were at increased risk of serious complications and death from the virus. The SARS-CoV-2 virus can directly affect the heart and blood vessels, exacerbating conditions such as inflammation and blood clotting. In addition, pandemic-related restrictions and lifestyle changes have increased risk factors for heart disease. This review aims to examine the impact of COVID-19 on patients with cardiovascular disease. Numerous studies have shown that individuals with cardiovascular disease are more susceptible to the virus, with cardiac problems being particularly prevalent in this patient population. In addition to the increased risk of cardiovascular complications, these patients also face a higher risk of mortality. For this purpose, scientific articles related to COVID-19, coronavirus, SARS-CoV-2, and cardiovascular diseases were collected and analyzed from reputable scientific sources, including PubMed, Scopus, Web of Science, and other scientific databases. The literature review revealed that coronavirus and COVID-19 caused various diseases and complications during the COVID-19 pandemic, including vascular complications, arrhythmias, pericarditis, myocarditis, and general cardiac involvement. Based on these findings, this study underscores the need for increased attention to patients with cardiovascular disease during the COVID-19 pandemic and highlights the need for specific and effective treatments for these patients based on the latest scientific evidence.
1. Mohammadian Amiri M., Dastyar N., Khajoei Nejad F., Ahmadi M., Piri N., Manouchehri A., Shokri S., 2022. The outbreak of post-traumatic stress disturbances during the COVID-19 pandemic: A systematic review. Caspian J Environ Sci. 20(5), 1149–1157. doi: 10.22124/cjes.2022.6096.
2. Gheidari M.E., Geramifard A., Rafiei M., 2024. Dysregulation of LncRNAs ANRIL, MALAT1, and LINC00305 in Coronary Slow Flow Patients: Implications for Inflammation and Endothelial Dysfunction. Int J Mol Cell Med. 13(1), 91–104. URL: http://ijmcmed.org/article-1-2363-en.html.
3. Aleksandrovna Kormishkina L., Danilovich Kormishkin E., Koloskov D.A., 2022. Environmental investment, the main condition for the COVID-19 post-pandemic recovery of Russian economy and transition to sustainable economic growth. Caspian J Environ Sci. 20(5), 1069–1082. doi: 10.22124/cjes.2022.6081.
4. Azar Bahadori R., Shabani D., Arjmandrad E., Kazerani M., Rohani M., Ramazani Karim Z., Ali-Kheyl M., Nosratabadi R., Pourghadamyari H., Zaemi M.A., 2024. Circulating miRNA-106b-5p as a potential biomarker for coronary artery disease. Int J Mol Cell Med. 13(3), 325–336. URL: http://ijmcmed.org/article-1-2256-en.html.
5. Heryadi D.Y., Tannady H., Dwinoor Rembulan G., Rofatin B., Siti Sundari R., 2023. Changes in behavior and welfare of organic rice farmers during the COVID-19 pandemic. Caspian J Environ Sci. 21(1), 191–197. doi: 10.22124/cjes.2023.6220.
6. Hassanzadeh Khanmiri H., Mohammad A.A., Yousif R.S., Jasim S.A., Kzar H.H., Lafta M.H., Jalil A.T., Romero Parra R.M., Darvishi M., 2023. SARS-CoV2 neuroinvasive potential in respiratory failure in COVID-19 patients. Caspian J Environ Sci. 21(2), 467–472. doi: 10.22124/cjes.2023.6635.
7. Widoyo H., Mohammed Z.Y., Ramírez-Coronel A.A., Iswanto A.H., Thattarauthodiyil U., Alkhayyat A.S., Karimi M., Bahmani M., Eftekhari Z., 2023. Herbal therapy in COVID-19: A systematic review of medicinal plants effective against COVID-19. Caspian J Environ Sci. 21(5), 1289–1298. doi: 10.22124/cjes.2023.7431.
8. Padma Priya S., Sunil P.M., Varma S., Brigi C., Isnadi M.F.A.R., Jayalal J.A., Shadamarshan R.A., Kumar S.S., Kumari N.V., Kumar R.P.R.., 2022. Direct, indirect, post-infection damages induced by coronavirus in the human body: an overview. Virusdisease. 33(4), 429–444.
9. Chen Y., Gong X., Wang L., Guo J., 2020. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: A systematic review and meta-analysis. MedRxiv. 2020(03), 1–13.
10. Vinayagam S., Sathishkumar, Kamaraj S., 2020. SARS-CoV-2 and coagulation disorders in different organs. Life Sci. 260, 118431.
11. Priya S.P., Sunil P.M., Varma S., Brigi C., Abd Rachman Isnadi M.F., Jayalal J.A., Shadamarshan R.A., Kumar S.S., Kumari N.V., Kumar R.P.R., 2021. Clotting disorder in severe acute respiratory syndrome coronavirus 2. Rev Med Virol. 31(3), e2177.
12. Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C., 2020. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 17(9), 543–558.
13. Imazio M., Gaita F., 2017. Acute and recurrent pericarditis. Cardiol Clin. 35(4), 505–513.
14. Tong Y., Bao A., Chen H., Huang J., Lv Z., Feng L., Cheng Y., Wang Y., Bai L., Rao W., Zheng H., 2020. Necessity for detection of SARS-CoV-2 RNA in multiple types of specimens for the discharge of the patients with COVID-19. J Transl Med. 18(1), 1–8.
15. Amoozgar B., Kaushal V., Mubashar U., Sen S., Yousaf S., Yotsuya M., 2020. Symptomatic pericardial effusion in the setting of asymptomatic COVID-19 infection: a case report. Medicine. 99(37), e2177.
16. Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 395(10229), 1054–1062.
17. Imazio M., Gaita F., 2015. Diagnosis and treatment of pericarditis. Heart. 101(14), 1159–1168.
18. Sandhu T., Tieng A., Chilimuri S., Franchin G., 2020. A case control study to evaluate the impact of colchicine on patients admitted to the hospital with moderate to severe COVID- infection. Can J Infect Dis Med Microbiol. 2020, 1–7. doi: 10.1155/2020/8865954.
19. Zhu H., Rhee J.W., Cheng P., Waliany S., Chang A., Witteles R.M., 2020. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep. 22(5), 1–9.
20. Ranard L.S., Fried J.A., Abdalla M., Anstey D.E., Givens R.C., Kumaraiah D., 2020. Approach to acute cardiovascular complications in COVID-19 infection. Circ Heart Fail. 13(7), e007220
21. Lazaridis C., Vlachogiannis N.I., Bakogiannis C., Spyridopoulos I., Stamatelopoulos K., Kanakakis I., 2020. Involvement of cardiovascular system as the critical point in coronavirus disease 2019 (COVID-19) prognosis and recovery. Hellenic J Cardiol. 2020.
22. Talasaz A.H., Kakavand H., Van Tassell B., Aghakouchakzadeh M., Sadeghipour P., Dunn S., Geraiely B., 2021. Cardiovascular complications of COVID-19: Pharmacotherapy perspective. Cardiovasc Drugs Ther. 1–11.
23. Wu L., O'Kane A.M., Peng H., Bi Y., Motriuk-Smith D., Ren J., 2020. SARS-CoV-2 and cardiovascular complications: from molecular mechanisms to pharmaceutical management. Biochem Pharmacol. 114114.
24. Nishiga M., Wang D.W., Han Y., Lewis D.B., Wu J.C., 2020. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 17(9), 543–558.
25. Loungani R.S., Rehorn M.R., Newby L.K., Katz J.N., Klem I., Mentz R.J., Jones W.S., Vemulapalli S., Kelsey A.M., Blazing M.A., Piccini J.P., Patel M.R., 2020. A care pathway for the cardiovascular complications of COVID-19: insights from an institutional response. Am Heart J. 225, 3–9.
26. Revzin M.V., Raza S., Warshawsky R., D'Agostino C., Srivastava N.C., Bader A.S., Malhotra A., Patel R.D., Chen K., Kyriakakos C., Pellerito J.S., 2020. Multisystem imaging manifestations of COVID-19, part 1: viral pathogenesis and pulmonary and vascular system complications. Radiographics. 40(6),1574–1599.
27. Iqbal F., Ehteshami Afshar E., Lewis J., Thakrar M., Kularatne M., Helmersen D., Parmar J., Hunter A., 2020. Novel insights on the pulmonary vascular consequences of COVID-19. Am J Physiol Lung Cell Mol Physiol. 319(2), 277–288.
28. Grillet F., Behr J., Calame P., Aubry S., Delabrousse E., 2020. Acute pulmonary embolism associated with COVID-19 pneumonia detected with pulmonary CT angiography. Radiol. 296(3), 186–E188.
29. Mak S.M., Mak D., Hodson D., Preston R., Retter A., Camporota L., 2020. Pulmonary ischemia without pulmonary arterial thrombus in COVID-19 patients receiving extracorporeal membrane oxygenation: a cohort study. Clin Radiol. 75(10), 795–805.
30. Viswanathan V., Puvvula A., Jamthikar A.D., Saba L., Johri A.M., Kotsis V., 2021 Bidirectional link between diabetes mellitus and coronavirus disease 2019 leading to cardiovascular disease: a narrative review. World J Diab. 12(3), 215.
31. Giustino G., Croft L.B., Stefanini G.G., Bragato R., Silbiger J.J., Vicenzi M., Danilov T., Kukar N., Shaban N., Kini A., Camaj A., Bienstock S.W., Rashed E.R., Rahman K., Oates C.P., Buckley S., Elbaum L.S., Arkonac D., Fiter R., Singh R., Li E., Razuk V., Robinson S.E., Miller M., Bier B., Donghi V., Pisaniello M., Mantovani R., Pinto G., Rota I., Baggio S., Chiarito M., Fazzari F., Cusmano I., Curzi M., Ro R., 2020. Characterization of myocardial injury in patients with COVID-19. J Am Coll Cardiol. 76(18), 2043–2055.
32. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L., Bi Z., Zhao Y., 2020. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 109(5), 531–538.
33. Zheng Y.Y., Ma Y.T., Zhang J.Y., Xie X., 2020. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 17(5), 259–260.
34. Zhu H., Rhee J.W., Cheng P., Waliany S., Chang A., Witteles R.M., Maecker H., Davis M.M., Nguyen P.K., Wu S.M., 2020. Cardiovascular complications in patients with COVID-19: consequences of viral toxicities and host immune response. Curr Cardiol Rep. 22(5), 1–9.
35. Balanzá–Martínez V., Atienza–Carbonell B., Kapczinski F., De Boni R.B., 2020. Lifestyle behaviours during the COVID‐19 – time to connect. Acta Psychiatr Scand. 141(5), 399.
36. Li M., Dong Y., Wang H., Guo W., Zhou H., Zhang Z., Du K., Zhu R. , Wang F., 2020. Cardiovascular disease potentially contributes to the progression and poor prognosis of COVID-19. Nutr Metab Cardiovasc Dis. 30(7), 1061–1067.
37. Khera A., Baum S.J., Gluckman T.J., Gulati M., Martin S.S., Michos E.D., 2020. Continuity of care and outpatient management for patients with and at high risk for cardiovascular disease during the COVID-19 pandemic: a scientific statement from the American Society for Preventive Cardiology. Am J Prev Cardiol. 1(1), 100009.